Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
View Patent ↗The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine containing nucleic acids encoding HIV-1 gag mosaic proteins, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
1. A nucleic acid encoding any one of the mosaic Gag polypeptide Gag M4.1-4Dmyr selected from the group consisting of SEQ ID NOs: 173-176.
2. A vector comprising the nucleic acid according to claim 1 .
3. The vector according to claim 2 , wherein said vector is a viral vector.
4. A composition comprising at least one nucleic acid according to claim 1 and a carrier.
5. A method of inducing an immune response in a mammal comprising administering to said mammal of at least one nucleic acid according to claim 1 operably linked to a promoter capable of directing expression of the polypeptide, in an amount sufficient to effect said induction.
6. The nucleic acid according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 173.
7. The nucleic acid according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 174.
8. The nucleic acid according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 175.
9. The nucleic acid according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 176.
10. The vector according to claim 2 , wherein the nucleic acid is present in the vector operably linked to a promoter.
11. The vector according to claim 2 , wherein the vector is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector or a Tobacco Mosaic Virus vector.
12. The composition according to claim 4 comprising nucleic acids encoding the four mosaic Gag polypeptide Gag M4.1-4Dmyr of SEQ ID NOs: 173-176.
13. The composition according to claim 4 , further comprising an adjuvant.
14. The composition according to claim 12 , further comprising an adjuvant.
15. A method of inducing an immune response in a mammal comprising administering to said mammal nucleic acids according to the composition of claim 12 , wherein each nucleic acid is operably linked to a promoter capable of directing expression of the polypeptide, in an amount sufficient to effect said induction.
16. The method according to claim 15 , wherein each nucleic acid is present in a vector.
17. The method according to claim 16 , wherein the vector is a viral vector.
18. The method according to claim 16 , wherein the vector is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector or a Tobacco Mosaic Virus vector.